Literature DB >> 2965228

Effect of regression of left ventricular hypertrophy following sotalol therapy on diastolic function in hypertensive patients.

M M Ibrahim1, S S Zaghloul, S M Helmi.   

Abstract

The effects of changes in left ventricular mass following beta-adrenergic blockade therapy (sotalol) on left ventricular filling indices were examined in 16 patients with essential hypertension aged 46 +/- 8.3 years (mean +/- s.d.). The peak atrial to peak early diastolic velocity (A:E) ratio and the peak filling rate (PFR = peak early diastolic velocity X mitral annulus area) were measured by the use of pulsed Doppler left ventricular inflow time-velocity plots following placebo and after 8-12 weeks of sotalol monotherapy (160 mg/day). Compared with normal controls of similar age, our patients had a larger left ventricular mass and impaired left ventricular filling indices. Following sotalol, mean arterial pressure (MAP) decreased by 14%, the heart rate by 15% and left ventricular mass by 11%, while diastolic filling improved (A:E 17% and PFR 21%). Six patients had a decrease in left ventricular mass of greater than 15% (group A); other patients (group B) showed a smaller reduction. In spite of comparable changes in MAP and heart rate in groups A and B, the patients in group A showed a smaller degree of improvement in the A:E ratio. It is concluded that sotalol can induce regression of left ventricular hypertrophy and improve left ventricular filling in hypertensive patients, and it seems that improvement in diastolic filling is related to a reduction in afterload rather than to a decrease in left ventricular mass.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2965228

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  3 in total

1.  Left ventricular diastolic function during adrenergic stress in essential hypertension: acute and chronic effects of ACE inhibition.

Authors:  G Covi; I Sheiban; G Gelmini; G Arcaro; S Tonni; A Bolner; G Piemonte; A Lechi
Journal:  Cardiovasc Drugs Ther       Date:  1996-07       Impact factor: 3.727

Review 2.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 3.  Myocardial hypertrophy and its role in heart failure with preserved ejection fraction.

Authors:  Frank R Heinzel; Felix Hohendanner; Ge Jin; Simon Sedej; Frank Edelmann
Journal:  J Appl Physiol (1985)       Date:  2015-07-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.